U.S. Patent Approval for its Formulation of Latanoprost in its Proprietary Controlled Release Insert

BioLight announces that ViSci, its wholly owned subsidiary, has been informed that a patent number 8,722,739 covering the proprietary formulation of Latanoprost,the medication contained in its controlled release insert for the treatment of Glaucoma, has been granted by the U.S. Patent and Trademark Office. The patent is intended to protect, inter …

Continue reading

BioLight Raises NIS 19 Million

BioLight announces the successful completion of an equity financing that raised gross proceeds of approximately NIS 19 million (USD 5.5 million).

Separately, BioLight announces that its subsidiary, IOPtima Ltd. a developer of minimally invasive ophthalmic surgery devices, received China Food and Drug Administration (CFDA) approval to market and sell the IOPtiMate™ …

Continue reading